ADC Therapeutics SA Share Holder Equity 2019-2022 | ADCT

ADC Therapeutics SA share holder equity from 2019 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
ADC Therapeutics SA Annual Share Holder Equity
(Millions of US $)
2021 $166
2020 $336
2019 $111
2018 $126
ADC Therapeutics SA Quarterly Share Holder Equity
(Millions of US $)
2022-06-30 $115
2022-03-31 $163
2021-12-31 $166
2021-09-30 $187
2021-06-30 $244
2021-03-31 $298
2020-12-31 $336
2020-09-30 $376
2020-06-30 $196
2020-03-31 $0
2019-12-31
2019-09-30 $0
2019-06-30 $0
2018-12-31 $126
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.392B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $152.564B 9.26
GSK (GSK) United Kingdom $61.844B 7.43
Bio-Rad Laboratories (BIO.B) United States $13.545B 29.93
QIAGEN (QGEN) Netherlands $9.898B 16.57
Ginkgo Bioworks Holdings (DNA) United States $5.908B 0.00
Myovant Sciences (MYOV) United Kingdom $2.391B 0.00
Arcus Biosciences (RCUS) United States $2.007B 39.18
Emergent Biosolutions (EBS) United States $1.039B 6.02
Biohaven Pharmaceutical Holding (BHVN) United States $0.878B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.113B 0.00
Gelesis Holdings (GLS) United States $0.087B 0.00
SQZ Biotechnologies (SQZ) United States $0.075B 0.00
Ambrx Biopharma (AMAM) United States $0.045B 0.00